The Swedish government has made major investments in the country’s life sciences research infrastructure; the latest research bill setting new record levels. SciLifeLab and Max IV are both national resources. ESS, The European Spallation Source, which is intended to become a resource for European scientists, is under development. These resources are intended for advancing the understanding of human biology and hence leading to new innovations in the fields of prevention, diagnosis and treatment.
Supporting life science research has long been a priority for the Swedish government. State-of the art research infrastructure has already been built and life science research continues to receive large share of the overall state research budget. Swedish companies and researchers also actively participate in EU-funded and other international projects. Professors at medical faculties can be co-appointed to university hospital positions which has proved instrumental in stimulating translational research. In addition, Swedish academia has always shown a willingness to collaborate with industry. And you will find opinion leaders in many research fields. Swedish medical research is leading in a number of areas. The government's pinpointed areas for strategic funding include the areas listed below (complementing the areas highlighted elsewhere on this website):
- Ageing and health
- Clinical Therapy Research
- Further expanding the use of and improving the quality registries
- Infection and antibiotic resistance
- Oncology and regional cancer centres
Complementary to the funding of strategic areas listed above, the government, through Vinnova, has invested in two long-term strategic innovation programs, SWElife and Medtech4Health. Academia, healthcare providers, research infrastructure including biobanks, incubators, investors and industry are all involved and the aim is to accelerate innovation and collaboration within drug development and medtech. Sweden has several well established testbeds and innovations hubs that are actively engaged in the programs in order to co-create new innovative treatments.